Comparative analysis of the information reported on labels of medicinal products containing new active substances between Europe and the USA.
Annali dell Istituto Superiore di Sanità · 17.06.2026 · 62 (2) · 115-120
DOI: 10.4415/ann_26_02_03 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Annali dell Istituto Superiore di Sanità, erschienen am 17.06.2026. Verfasst von Giuseppe Marano und 5 weiteren Autor:innen. Beteiligte Einrichtung: Centro Nazionale per la Ricerca e la Valutazione Preclinica e Clinica dei Farmaci, Istituto Superiore di Sanità, Rome, Italy. Hauptthemen laut MEDLINE: Drug Labeling.
Abstract (Originalsprache)
Introduction
Although notable efforts have been made to harmonise regulatory processes for the approval of new therapeutic drugs by the competent authorities, some discrepancies concerning risk-benefit assessments and regulatory actions remain.
Methods
This analysis compared the approaches of the European Medicines Agency (EMA) and the US Food and Drug Administration (FDA) in the approval of new active substances and identified potential clinical implications associated with these differences in “Indication”, “Contraindications” and “Posology and administration of drugs” sections of drug summary of products characteristics (SmPC).
Results
The overall analysis showed major differences in 63.9% for the indications, in 75% for contraindications and in 13.9% for posology. Considering the more represented therapeutic areas (cancer and haematology/haemostaseology drugs), the percentage of major differences for the indications was 70% in cancer area and 50% in haematology/ haemostaseology area. For contraindications major differences were observed in 90% of cancer drugs, and 60% in haematology/haemostaseology drugs.
Discussion
Our findings highlight the need of further efforts on harmonizing decision making driven by scientific data between regulatory authorities in the interest of patients in a public health perspective.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Centro Nazionale per la Ricerca e la Valutazione Preclinica e Clinica dei Farmaci, Istituto Superiore di Sanità, Rome, Italy.
Zitieren
APA
Marano, G., Annunziata, A., Cutillo, M., Da Cas, R., Menniti-Ippolito, F., & Ippoliti, I. (2026). Comparative analysis of the information reported on labels of medicinal products containing new active substances between Europe and the USA. Annali dell Istituto Superiore di Sanità, 62(2), 115-120. https://doi.org/10.4415/ann_26_02_03
Vancouver
Marano G, Annunziata A, Cutillo M, Da Cas R, Menniti-Ippolito F, Ippoliti I. Comparative analysis of the information reported on labels of medicinal products containing new active substances between Europe and the USA. Annali dell Istituto Superiore di Sanità. 2026;62(2):115-120. doi:10.4415/ann_26_02_03
BibTeX
@article{Marano2026,
author = {Marano, Giuseppe and Annunziata, Arianna and Cutillo, Maria and Da Cas, Roberto and Menniti-Ippolito, Francesca and Ippoliti, Ilaria},
title = {Comparative analysis of the information reported on labels of medicinal products containing new active substances between Europe and the USA},
journal = {Annali dell Istituto Superiore di Sanità},
year = {2026},
volume = {62},
number = {2},
pages = {115--120},
doi = {10.4415/ann_26_02_03}
}
EUVIMED